The Effectiveness of a Thyme and Honey Spray for Oral Toxicities

NCT ID: NCT04880148

Last Updated: 2021-12-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-11-03

Study Completion Date

2024-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Aim: To evaluate the effectiveness of thymus honey on radiation induced-oral mucositis and xerostomia.

Background: Oral mucositis and xerostomia are two of the most severe side effects that head and neck cancer patients confront during and after the completion of radiotherapy. Although several medications are used for their treatment, these fail to provide a fully effective and comprehensive management. Honey and thyme have been studied for the management of various treatment-related side effects.

Design: Α double blinded randomised controlled trial will be used for this study.

Methods: 200 head and neck cancer patients who receive radiotherapy will be included in this study. Patients will be randomised and divided into two equal groups of 100 participants; the intervention group (oral spray with thyme and honey + standard care) and the control group ( placebo spray + standard care). Assessments with xerostomia and oral mucositis scales additionally to 4 self-administered questionnaires will occur in both groups at baseline and then weekly and 6 months following completion of treatment. The duration of the study will be 3 years from the day of approval of this research protocol.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer of the Head and Neck Xerostomia Oral Mucositis Radiation Toxicity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Thyme and Honey-based oral spray

Thyme and Honey-based oral spray

Group Type EXPERIMENTAL

Thyme and Honey-based oral spray

Intervention Type DIETARY_SUPPLEMENT

4 X Sprays in the oral cavity before, immediately after and 6 hours following the radiotherapy session

Placebo oral spray

Placebo oral spray

Group Type PLACEBO_COMPARATOR

Placebo oral spray

Intervention Type DIETARY_SUPPLEMENT

4 X Sprays in the oral cavity before, immediately after and 6 hours following the radiotherapy session

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Thyme and Honey-based oral spray

4 X Sprays in the oral cavity before, immediately after and 6 hours following the radiotherapy session

Intervention Type DIETARY_SUPPLEMENT

Placebo oral spray

4 X Sprays in the oral cavity before, immediately after and 6 hours following the radiotherapy session

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with a confirmed histologic diagnosis of head and neck cancer
* Patients referred to non-palliative radiotherapy to the oral cavity will be included in the study
* Synchronous or induction chemotherapy, or both, will be permitted.
* Patients aged over 18,
* Patients able to provide informed consent,
* Patients having radiotherapy for at least three weeks (lower limit has been set at 50 Gy),
* Patients able to complete records accurately

Exclusion Criteria

* Patients with a confirmed and medically treated diabetes mellitus,
* Patients with allergy to honey, thyme or any other ingredient,
* Patients who will refuse to take part in this study and
* Patients with previous radiotherapy or presence of systemic disease.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

German Oncology Center, Cyprus

OTHER

Sponsor Role collaborator

Bank of Cyprus Oncology Center BOCOC

UNKNOWN

Sponsor Role collaborator

Cyprus University of Technology

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr. Andreas Charalambous

Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Andreas Charalambous, PhD

Role: PRINCIPAL_INVESTIGATOR

Cyprus University of Technology

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

German Oncology Center

Limassol, , Cyprus

Site Status RECRUITING

Bank of Cyprus Oncology Center

Nicosia, , Cyprus

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Cyprus

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Andreas Charalambous, PhD

Role: CONTACT

Phone: 25002011

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Konstantinos Ferentinos, MD, PhD

Role: primary

Constantina Cloconi, MSc, RN

Role: backup

Dimitrios Vomvas, PhD

Role: primary

Morfo Georgiou, MD

Role: backup

References

Explore related publications, articles, or registry entries linked to this study.

Thrasyvoulou S, Tsitsi T, Katodritis N, Vomvas D, Charalambous M, Charalambous A. Reliability and Validity of the Greek Version of the Oral Mucositis Weekly Questionnaire in the Head and Neck Cancer Context. J Nurs Meas. 2021 Aug 1;29(2):317-333. doi: 10.1891/JNM-D-19-00096. Epub 2021 Mar 19.

Reference Type BACKGROUND
PMID: 33741726 (View on PubMed)

Charalambous A. Hermeneutic phenomenological interpretations of patients with head and neck neoplasm experiences living with radiation-induced xerostomia: the price to pay? Eur J Oncol Nurs. 2014 Oct;18(5):512-20. doi: 10.1016/j.ejon.2014.04.007. Epub 2014 May 27.

Reference Type BACKGROUND
PMID: 24877858 (View on PubMed)

Charalambous M, Raftopoulos V, Paikousis L, Katodritis N, Lambrinou E, Vomvas D, Georgiou M, Charalambous A. The effect of the use of thyme honey in minimizing radiation - induced oral mucositis in head and neck cancer patients: A randomized controlled trial. Eur J Oncol Nurs. 2018 Jun;34:89-97. doi: 10.1016/j.ejon.2018.04.003. Epub 2018 Apr 30.

Reference Type RESULT
PMID: 29784145 (View on PubMed)

Charalambous A, Lambrinou E, Katodritis N, Vomvas D, Raftopoulos V, Georgiou M, Paikousis L, Charalambous M. The effectiveness of thyme honey for the management of treatment-induced xerostomia in head and neck cancer patients: A feasibility randomized control trial. Eur J Oncol Nurs. 2017 Apr;27:1-8. doi: 10.1016/j.ejon.2017.01.001. Epub 2017 Jan 16.

Reference Type RESULT
PMID: 28279391 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

21-HONEY-CUT

Identifier Type: -

Identifier Source: org_study_id